Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on May 5, 2011. The report discloses a corporate governance event regarding the granting of equity awards to employees under the Company's 2011 Stock Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and equity grants rather than financial performance.
Material Changes
On May 5, 2011, the Board of Directors granted restricted stock units (RSUs) to senior management and restricted stock awards to other employees. Key details include:
- Grant Date: May 10, 2011
- Vesting Date: May 15, 2012
- Vesting Conditions: Based on the achievement of pre-determined business development, clinical development, and regulatory events, contingent upon continuous service through the vesting date.
RSU grants for Named Executive Officers are as follows:
| Executive Officer | Title | RSU Grant |
|---|---|---|
| Gregory I. Frost, Ph.D. | President and CEO | 26,000 |
| Kurt A. Gustafson | VP, Secretary and CFO | 24,000 |
| William J. Fallon | VP, Manufacturing and Operations | 19,000 |
| H. Michael Shepard, Ph.D. | VP, Chief Scientific Officer | 18,000 |
| Michael J. LaBarre, Ph.D. | VP, Product Development | 19,000 |
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or general risk factors. However, it notes a specific contingency regarding the equity awards: vesting is conditional upon the achievement of specific business, clinical, and regulatory milestones.
Investor Verification Checklist
- Verify the specific "pre-determined business development, clinical development and regulatory events" required for the May 15, 2012 vesting.
- Review the Company's 2011 Stock Plan to understand the total pool of shares available and the impact of these grants on dilution.
- Confirm the fair value of the RSUs granted for accounting and expense recognition purposes in future financial statements.